SHANK2 mutations result in dysregulation of the ERK1/2 pathway in human induced pluripotent stem cells-derived neurons and Shank2(- /- ) Mice

peer-reviewed
Erstveröffentlichung
2021-11-26Authors
Lutz, Anne-Kathrin
Pérez Arévalo, Andrea
Ioannidis, Valentin
Stirmlinger, Nadine
Demestre, Maria
Wissenschaftlicher Artikel
Published in
Frontiers in Molecular Neuroscience ; 14 (2021). - Art.-Nr. 773571. - eISSN 1662-5099
Link to original publication
https://dx.doi.org/10.3389/fnmol.2021.773571Faculties
Medizinische FakultätInstitutions
Institut für Anatomie und ZellbiologieExternal cooperations
L’hôpital Robert-DebréInstitut Pasteur
Université de Paris
Deutsches Zentrum für Neurodegenerative Erkrankungen
Document version
published version (publisher's PDF)Abstract
SHANK2 (ProSAP1) is a postsynaptic scaffolding protein of excitatory synapses in the
central nervous system and implicated in the development of autism spectrum disorders
(ASD). Patients with mutations in SHANK2 show autism-like behaviors, developmental
delay, and intellectual disability. We generated human induced pluripotent stem cells
(hiPSC) from a patient carrying a heterozygous deletion of SHANK2 and from the
unaffected parents. In patient hiPSCs and derived neurons SHANK2 mRNA and
protein expression was reduced. During neuronal maturation, a reduction in growth
cone size and a transient increase in neuronal soma size were observed. Neuronal
proliferation was increased, and apoptosis was decreased in young and mature
neurons. Additionally, mature patient hiPSC-derived neurons showed dysregulated
excitatory signaling and a decrease of a broad range of signaling molecules of the
ERK-MAP kinase pathway. These findings could be confirmed in brain samples from
Shank2(-/-) mice, which also showed decreased mGluR5 and phospho-ERK1/2
expression. Our study broadens the current knowledge of SHANK2-related ASD. We
highlight the importance of excitatory-inhibitory balance and mGluR5 dysregulation
with disturbed downstream ERK1/2 signaling in ASD, which provides possible future
therapeutic strategies for SHANK2-related ASD.
EU Project uulm
AIMS-2-TRIALS / Autism Innovative Medicine Studies - 2 - Trials / EC / H2020 / 777394
CANDY / Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy / EC / H2020 / 847818
CANDY / Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy / EC / H2020 / 847818
DFG Project THU
SFB 1149 / Gefahrenantwort, Störfaktoren und regeneratives Potential nach akutem Trauma / DFG / 251293561
Publication funding
Open-Access-Förderung durch die Medizinische Fakultät der Universität Ulm
Is supplemented by
https://www.frontiersin.org/articles/10.3389/fnmol.2021.773571/full#supplementary-materialSubject headings
[GND]: Induzierte pluripotente Stammzelle[MeSH]: MAP Kinase Signaling System
[Free subject headings]: SHANK2 | hiPSCs | ERK1/2 | Neurodevelopment | ASD
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item recordDOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-40117
Lutz, Anne-Kathrin et al. (2021): SHANK2 mutations result in dysregulation of the ERK1/2 pathway in human induced pluripotent stem cells-derived neurons and Shank2(- /- ) Mice. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. http://dx.doi.org/10.18725/OPARU-40117
Citation formatter >